Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7MW3711 Compared With Docetaxel in sqNSCLC
NCT07831863Phase 3Not yet recruiting
- Sponsor
- Mabwell
- Start
- Oct 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of 7MW3711 in squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by Mabwell. Primary endpoint: Overall Survival up to 34 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
7MW3711
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT07831863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07831863.